Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1801 to 1815 of 8320 results

  1. Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]

    Awaiting development Reference number: GID-TA11743 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]

    Awaiting development Reference number: GID-TA11667 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    In development Reference number: GID-TA11535 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Ruxolitinib for Prurigo Nodularis [ID6571]

    In development Reference number: GID-TA11760 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]

    Awaiting development Reference number: GID-TA11720 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Elinzanetant for Vasomotor symptoms [ID6544]

    Awaiting development Reference number: GID-TA11784 Expected publication date:  21 July 2027

    Technology appraisal guidance
    Awaiting development

  7. Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]

    Awaiting development Reference number: GID-TA11721 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]

    Awaiting development Reference number: GID-TA11692 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [TSID9130]

    Awaiting development Reference number: GID-TA11325 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]

    In development Reference number: GID-TA11749 Expected publication date:  10 June 2027

    Technology appraisal guidance
    In development

  11. Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6566]

    Awaiting development Reference number: GID-TA11748 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]

    Awaiting development Reference number: GID-TA11755 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]

    Awaiting development Reference number: GID-TA11754 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma after 3 or more treatment lines [ID6549]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546]

    Awaiting development Reference number: GID-TA11724 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development